Descriptive characteristics of the study population composed of 92 patients
| Variable | Overall (n = 92*) | No PCa (n = 37, 40.2%) | PCa (n = 55, 59.8%) | P value |
|---|---|---|---|---|
| Age (years) | 67 [61.8–74.2] | 64 [60–69] | 71 [63–76] | <0.01 |
| PSA level (ng/mL) | 6.3 [4.3–9.9] | 5.3 [4–7.9] | 7.4 [4.8–10.4] | <0.05 |
| Prostate volume (mL) | 55 [40–70] | 60 [45–73] | 50 [38–70] | 0.17 |
| GGG | ||||
| 1 | 13 (14.1) | 0 (0) | 13 (23.6) | |
| 2 | 18 (19.6) | 0 (0) | 18 (32.7) | |
| 3 | 13 (14.1) | 0 (0) | 13 (23.6) | |
| 4 | 7 (7.6) | 0 (0) | 7 (12.7) | |
| 5 | 4 (4.3) | 0 (0) | 4 (7.3) | |
| Clinical T stage | 0.07 | |||
| 1 | 70 (76.1) | 32 (86.5) | 38 (69.1) | |
| 2 | 19 (20.7) | 4 (10.8) | 15 (27.3) | |
| 3 | 2 (2.2) | 0 (0) | 2 (3.6) | |
| PI-RADS score | <0.001 | |||
| 1 | 2 (2.2) | 2 (5.4) | 0 (0) | |
| 2 | 9 (9.8) | 7 (18.9) | 2 (3.6) | |
| 3 | 32 (34.8) | 18 (48.6) | 14 (25.5) | |
| 4 | 29 (31.5) | 8 (21.6) | 21 (38.2) | |
| 5 | 17 (18.5) | 0 (0) | 17 (30.9) |
BPH, benign prostatic hyperplasia; PCa, prostate cancer; PSA, prostate-specific antigen; GGG, Gleason grade group; PI-RADS, Prostate Imaging Reporting and Data System. Values are presented as median [interquartile range] or n (%). *Three of 92 patients had no PI-RADS value.